文献速递慢阻肺呼吸道感染

吸入激素、循环嗜酸性粒细胞、慢性气道感染与慢阻肺肺炎风险:网络分析

Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis.
PubMed 文献 · Am J Respir Crit Care Med · 2020-01-01

该研究为对201例慢阻肺(GOLD II-IV级)患者历史队列的回顾性长期观察的事后分析,中位随访84个月,采用多变量Cox回归和网络分析。结果显示慢性支气管感染(CBI)与血嗜酸性粒细胞<100/μl均独立关联肺炎风险,二者共存时风险更高,且ICS治疗在二者共存患者中进一步增加肺炎风险。

要点

  • 血嗜酸性粒细胞<100/μl且合并CBI的慢阻肺患者使用ICS时肺炎风险显著增加。
  • CBI与血嗜酸性粒细胞<100/μl独立关联肺炎风险,二者共存时风险更高。
  • 临床需综合评估血嗜酸性粒细胞计数与气道微生物状态以权衡ICS利弊。

核心结论

  • 血嗜酸性粒细胞<100/μl合并CBI增加接受ICS治疗的慢阻肺患者肺炎风险。

研究设计与样本

  • 对201例慢阻肺(GOLD II-IV级)历史队列进行回顾性长期观察的事后分析,中位随访84个月。
  • 采用多变量Cox回归和网络分析。

主要发现

  • 随访期间38.8%患者发生一次或多次肺炎。
  • CBI与肺炎风险独立相关(HR 1.635)。
  • 血嗜酸性粒细胞<100/μl与肺炎风险独立相关(HR 1.975)。
  • CBI与血嗜酸性粒细胞<100/μl共存时肺炎风险HR为3.126。
  • 在血嗜酸性粒细胞<100/μl且CBI患者中,ICS治疗增加肺炎风险(HR 2.925)。

关键数值与推荐

  • 患者平均年龄70.3岁,90.5%为男性,平均FEV1为49%。
  • 71.6%患者接受ICS治疗,57.2%合并支气管扩张,20.9%血嗜酸性粒细胞<100/μl。
  • 42.3%患者分离出病原微生物,22.4%符合CBI定义。

临床怎么用

  • 对血嗜酸性粒细胞<100/μl且存在CBI的慢阻肺患者,应谨慎评估ICS治疗获益与肺炎风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Treatment of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroids (ICS) is controversial, because it can reduce the risk of future exacerbations of the disease at the expense of increasing the risk of pneumonia.Objectives: To assess the relationship between the presence of chronic bronchial infection (CBI), reduced number of circulating eosinophils, ICS treatment, and the risk of pneumonia in patients with COPD.Methods: This was a post hoc long-term observational study of an historical cohort of 201 patients with COPD (Global Initiative for Chronic Obstructive Lung Disease II-IV) who were carefully characterized (including airway microbiology) and followed for a median of 84 months. Results were analyzed by multivariate Cox regression and network analysis.Measurements and Main Results: Mean age was 70.3 years, 90.5% of patients were male, mean FEV1 was 49%, 71.6% of patients were treated with ICS, 57.2% of them had bronchiectasis, and 20.9% had <100 blood eosinophils/μl. Pathogenic microorganisms were isolated in 42.3% of patients, and 22.4% of patients fulfilled the definition of CBI. During follow-up, 38.8% of patients suffered one or more episodes of pneumonia, with CBI (hazard ratio [HR], 1.635) and <100 eosinophils/μl (HR, 1.975) being independently associated with the risk of pneumonia, particularly when both coexist (HR, 3.126). ICS treatment increased the risk of pneumonia in those patients with <100 eosinophils/μl and CBI (HR, 2.925).Conclusions: Less than 100 circulating eosinophils/μl combined with the presence of CBI increase the risk of pneumonia in patients with COPD treated with ICS.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Martinez-Garcia MA, Faner R, Oscullo G, et al. Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis. Am J Respir Crit Care Med. 2020. PMID: 31922913. doi:10.1164/rccm.201908-1550OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。